2nd Quarter - Termination — JAMES P. KEESE for TEVA PHARMACEUTICALS USA (2009)

Firm

JAMES P. KEESE

Client

TEVA PHARMACEUTICALS USA

Income

$40,000

Expenses

—

Terminated

Jul 31, 2009

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Access to Life-Saving Medicine Act (H.R. 1038 & S. 623), Affordable Biologics for Consumers Act (S. 1505), Biologics Price Competition and Innovation Act of 2007 (S. 1695), Consumer Food Safety Act of 2008 (H.R. 3624), Fair Prescription Drug Competition Act (H.R. 806 & S. 438), Food and Drug Import Safety Act of 2007 (H.R. 3610, The Pathway for Biologics Act (H.R. 5629), The Patient Protection and Innovative Biologic Medicines Act (H.R. 1956).

Foreign entity interest: Teva Pharmaceuticals, Ltd., as an indirect parent of Teva Pharmaceuticals, USA, has an interest in the issues listed above.

Lobbyist	Covered position, as disclosed
JAMES P KEESE	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5629 (111th), H.R. 3624 (111th), H.R. 806 (111th), H.R. 1038 (111th), S. 1695 (111th), H.R. 3610 (111th), S. 623 (111th), S. 1505 (111th), H.R. 1956 (111th), S. 438 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.